Adolescent Master Protocol
Condition(s):HIV/AIDSLast Updated:November 13, 2023Completed
Hide Studies Not Open or Pending
Condition(s):HIV/AIDSLast Updated:November 13, 2023Completed
Condition(s):Central Venous Catheter; Catheter-Related Bloodstream Infection (CRBSI) NosLast Updated:November 5, 2019Completed
Condition(s):Syncope, Vasovagal; Postural Orthostatic Tachycardia Syndrome; Orthostatic IntoleranceLast Updated:November 27, 2023Recruiting
Condition(s):Acute Coronary Syndrome (ACS)Last Updated:December 30, 2015Completed
Condition(s):Bladder Diseases; Interstitial CystitisLast Updated:October 30, 2013Completed
Condition(s):Peripheral T Cell LymphomaLast Updated:November 18, 2023Recruiting
Condition(s):Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA; Alkylating Agent-Related Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome; Untreated Adult Acute Myeloid LeukemiaLast Updated:February 2, 2017Completed
Condition(s):Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative NeoplasmsLast Updated:June 27, 2013Completed
Condition(s):Acute Leukemia; Chronic Leukemia; Myelodysplastic Syndrome; Lymphoma; MyelomaLast Updated:November 30, 2015Terminated
Condition(s):Snake EnvenomationLast Updated:December 1, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.